MESO Mesoblast limited.

$MESO major good news out of Australia and revised Q1 profitability. Tomorrow could be fun

$MESO Follow-up: Mesoblast, maker of Ryoncil, an FDA-approved cell therapy for children with graft-versus-host disease, put preliminary Sept-quarter Ryoncil net revenue at US$28M, down ~22% from the US$36M June-quarter figure in its Aug 27, 2026 results deck. That is still up 44% from US$19M a year earlier; the company blames July-August summer scheduling and says September had its most new patient starts per month. Cash was US$99M at Sept 30 (operating cash spend US$2.3M) vs a US$125M credit line drawn in full. Next: AGM Nov 10.

$MESO $MESO bull case is getting much easier to quantify: • RYONCIL generated $115.2M FY26 net revenue in its first full launch year • $103.6M gross profit on $120.3M total revenue • Net loss fell 44%; 2H operating cash burn was only $13.4M • More than 50 transplant centers onboarded, including 14 of the 15 largest pediatric sites • Coverage now exceeds 280M lives • Median time from patient identification to treatment improved from 29 days to 8 days • Adult aGvHD registrational trial is enrolling; management says that market is 3× larger than pediatrics • The 350-patient Phase 3 chronic low-back-pain trial is fully treated, with topline data expected mid-2027 • FDA just approved a new commercial RYONCIL potency assay, strengthening manufacturing consistency and scalability This is no longer a pre-revenue cell-therapy story: it now has a commercial product funding multiple late-stage expansion opportunities.

$MESO update on the mesoblast v. Capricor patent infringement suit. offical summons has been issued meaning that Capricor has now been officially served in the case and it is proceeding. Capricor has until November 3 to respond.

$MESO Big news included in their Q1 "Activity Report": "FDA confirmed the BLA filing may proceed for patients with life-threatening major gastrointestinal bleeding ...". This is for "patients with end-stage heart failure with reduced ejection fraction (HFrEF) being kept alive by a left ventricular assist device". It is not clear to me how much this will affect the stock price after the market opens. The key question is whether or not investors were already expecting such an announcement. The company was saying recently that they were meeting with the FDA to discuss a possible BLA submission related to HFrEF. However, this potential BLA submission has been "sitting on the shelf" for years. Perhaps investors were not expecting much from this FDA meeting, so the news is very positive. I think the stock will do moderately well near term. However, I will not invest long term due to future potential competition in CLBP from IDCT (rebonuputemcel, DiscGenics - a private, venture-backed company)

$MESO seems like there are no US retail investors left. Stock is up double digit percentage and not a single post about it. Is it bullish that mostly institutions own this now, or bearish? Asking into the ether.

$MESO getting some love in 24 hour trading on this Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) "Financial highlights included 44% increase in net revenues and 86% improvement in net operational cash spend compared with the prior year period."